Despite increasing evidence indicating that BRCA1-mutated breast cancer and TNBC confer sensitivity to platinum-derived compounds (Figure 2), randomized data comparing such platinum-based agents versus standard regimens for breast cancer patients in terms of efficacy and safety are still lacking and remain a subject of argument [49,68]. Here, BRCA1 is linked to breast cancer.